Combined treatment with Netrin-1 interfering drug and immune checkpoint inhibitors drugs
US12162932B2 · kind B2 · utility
0Cited by
2References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 5, 2018 |
| Grant date | Dec 10, 2024 |
| Priority date | — |
| Expiry date | Apr 2, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is the combination or combined use of (i) a compound able to disrupt or impede netrin-1/netrin-1 receptors interaction or netrin-1-mediated receptor dimerization, also called herein a NTN1 neutralizing agent, which compound may be an antibody binding to netrin-1 or anti-netrin-1 antibody, and (ii) an immune checkpoint inhibitor, in the treatment of cancer. The composition may comprise an anti-netrin-1 antibody and an immune checkpoint inhibitor, for use as an anticancerous drug with a simultaneous, separate or sequential administration of the anti-netrin-1 antibody and the immune checkpoint inhibitor to a patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.